UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of

                       the Securities Exchange Act of 1934

                     Date of Report (Date of earliest event
                                   reported):

                                 MARCH 14, 1997

                                 PROXYMED, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)



           FLORIDA                  0-22052                  65-0202059
           -------                  -------                  ----------
(State or other jurisdiction      (Commission            (IRS Employer
      of incorporation)            File Number)           Identification No.)

      2501 DAVIE ROAD, SUITE 230, FT. LAUDERDALE, FLORIDA           33317-7424
      ---------------------------------------------------           ----------
         (Address of principal executive offices)                   (Zip Code)

        Registrant's telephone number, including area code (954) 473-1001


<PAGE>



ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.

       (a) On March 14, 1997, the Company acquired substantially all of the
assets and certain of the liabilities of Clinical MicroSystems, Inc. ("CMS").
CMS is the developer of ClinScan, a physician desktop lab ordering and results
posting software used by over 100 labs and approximately 3,000 physicians
throughout the United States. The purchase price consisted of the following:
$3,000,000 in cash and 125,786 shares of unregistered common stock paid at
closing, plus $2,000,000 in cash and common stock payable over a three year
period as follows: $750,000, $500,000 and $750,000 in 12, 24 and 36 months
following the closing date, respectively. Each of the future payments will be at
least 50% in cash, with the remainder, if any, paid in the form of unregistered
common stock. The acquisition will be accounted for as a purchase. As part of
the transaction, the founder, sole shareholder and president of CMS, Glenn
Gilchrist, was appointed Senior Vice President of the Company pursuant to a two
year employment agreement which provides for minimum annual compensation of
$100,000.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

       (a) The audited financial statements required by Item 7(a) of CMS as of
and for the years ended December 31, 1996 and 1995 will be filed within 60 days
as an amendment to this Form 8-K.

       (b) The pro forma financial information required by Item 7(b) will be
filed within 60 days as an amendment to this Form 8-K.

       (c)  The following exhibit is included herein:

       Exhibit 1 - ASSET PURCHASE  AGREEMENT dated February 11, 1997 between 
ProxyMed,  Inc.,  Clinical  MicroSystems, Inc. and Glenn Gilchrist.

                                       2
<PAGE>



                                   SIGNATURES


       Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                PROXYMED, INC.

Date  MARCH 21, 1997                            /S/ BENNETT MARKS
      --------------                            -----------------
                                                Bennett Marks, Executive Vice
                                                President - Finance, Chief
                                                Financial Officer and Director

                                       3
<PAGE>


                               INDEX TO EXHIBITS


EXHIBIT
NUMBER              DESCRIPTION
-------             -----------

  1            Asset Purchase Agreement
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3924}]
{"company-data": {"conformed-name": "PROXYMED INC /FT LAUDERDALE/", "cik": "0000906337", "assigned-sic": "5912", "irs-number": "650202059", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-22052", "film-number": "97560432"}, "business-address": {"street1": "2501 DAVIE RD STE 230", "city": "FT LAUDERDALE", "state": "FL", "zip": "33317-7424", "phone": "3054731001"}, "former-company": {"former-conformed-name": "HMO PHARMACY INC", "date-changed": "19930601"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of

                       the Securities Exchange Act of 1934

                     Date of Report (Date of earliest event
                                   reported):

                                 MARCH 14, 1997

                                 PROXYMED, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)

           FLORIDA                  0-22052                  65-0202059
           -------                  -------                  ----------
(State or other jurisdiction      (Commission            (IRS Employer
      of incorporation)            File Number)           Identification No.)

      2501 DAVIE ROAD, SUITE 230, FT. LAUDERDALE, FLORIDA           33317-7424
      ---------------------------------------------------           ----------
         (Address of principal executive offices)                   (Zip Code)

        Registrant's telephone number, including area code (954) 473-1001
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.

       (a) On March 14, 1997, the Company acquired substantially all of the
assets and certain of the liabilities of Clinical MicroSystems, Inc. ("CMS").
CMS is the developer of ClinScan, a physician desktop lab ordering and results
posting software used by over 100 labs and approximately 3,000 physicians
throughout the United States. The purchase price consisted of the following:
$3,000,000 in cash and 125,786 shares of unregistered common stock paid at
closing, plus $2,000,000 in cash and common stock payable over a three year
period as follows: $750,000, $500,000 and $750,000 in 12, 24 and 36 months
following the closing date, respectively. Each of the future payments will be at
least 50% in cash, with the remainder, if any, paid in the form of unregistered
common stock. The acquisition will be accounted for as a purchase. As part of
the transaction, the founder, sole shareholder and president of CMS, Glenn
Gilchrist, was appointed Senior Vice President of the Company pursuant to a two
year employment agreement which provides for minimum annual compensation of
$100,000.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

       (a) The audited financial statements required by Item 7(a) of CMS as of
and for the years ended December 31, 1996 and 1995 will be filed within 60 days
as an amendment to this Form 8-K.

       (b) The pro forma financial information required by Item 7(b) will be
filed within 60 days as an amendment to this Form 8-K.

       (c)  The following exhibit is included herein:

       Exhibit 1 - ASSET PURCHASE  AGREEMENT dated February 11, 1997 between 
ProxyMed,  Inc.,  Clinical  MicroSystems, Inc. and Glenn Gilchrist.

                                       2
SIGNATURES

       Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                PROXYMED, INC.

Date  MARCH 21, 1997                            /S/ BENNETT MARKS
      --------------                            -----------------
                                                Bennett Marks, Executive Vice
                                                President - Finance, Chief
                                                Financial Officer and Director

                                       3
INDEX TO EXHIBITS

EXHIBIT
NUMBER              DESCRIPTION
-------             -----------

  1            Asset Purchase Agreement